Showing 301 - 320 results of 377 for search '"tyrosine kinase"', query time: 0.06s Refine Results
  1. 301

    Correlation between Apelin and Some Angiogenic Factors in the Pathogenesis of Preeclampsia: Apelin-13 as Novel Drug for Treating Preeclampsia and Its Physiological Effects on Place... by Reham Z. Hamza, Abdel Aziz A. Diab, Mansour H. Zahra, Ali K. Asalah, Suzan M. M. Moursi, Najah M. Al-Baqami, Fawziah A. Al-Salmi, Mai S. Attia

    Published 2021-01-01
    “…Moreover, serum apelin, placental growth factor (PLGF), vascular endothelial growth factor (VEGF), soluble fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin (sEng), interferon-gamma (IFN-γ), and interleukin-10 (IL-10) levels and serum superoxide dismutase enzyme (SOD) and catalase (CAT) activities of all groups were estimated at the end of experiment. …”
    Get full text
    Article
  2. 302

    Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States by Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Q. Wu, Pallavi Patwardhan

    Published 2022-08-01
    “…**Background:** Despite advances in tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia in chronic phase (CML-CP), a sizeable proportion of patients with CML-CP remains refractory or intolerant to these agents. …”
    Get full text
    Article
  3. 303

    Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs. by Pakorn Prakaikietikul, Pattraporn Tajarenmuang, Phumiphat Losuriya, Natee Ina, Thanika Ketpueak, Thanat Kanthawang

    Published 2025-01-01
    “…<h4>Purpose</h4>To identify non-cancerous factors from baseline CT chest affecting survival in advanced non-small cell lung cancer (NSCLC) treated with first-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs).<h4>Methods</h4>Retrospective study of 172 advanced NSCLC patients treated with first-generation EGFR-TKIs as a first-line systemic treatment (January 2012 to September 2022). …”
    Get full text
    Article
  4. 304

    PRMT1 Promotes the Self‐renewal of Leukemia Stem Cells by Regulating Protein Synthesis by Min Zhou, Yi Huang, Ping Xu, Shuyi Li, Chen Duan, Xiaoying Lin, Shilai Bao, Waiyi Zou, Jingxuan Pan, Chang Liu, Yanli Jin

    Published 2025-02-01
    “…Abstract The application of tyrosine kinase inhibitors (TKIs) has revolutionized the management of chronic myeloid leukemia (CML). …”
    Get full text
    Article
  5. 305

    Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma by Zhaosong Xue, Ming Yao, Kang Chen, Taiyun Huang, Jianjun Li, Jian Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan

    Published 2025-02-01
    “…Abstract  Combining local interventions with tyrosine kinase inhibitors (TKIs) plus anti-PD-1 antibodies in a triple therapy has demonstrated remarkable anti-tumor efficacy and facilitated conversion resection in patients with initially unresectable hepatocellular carcinoma (HCC). …”
    Get full text
    Article
  6. 306

    Nicotine is associated with smoking dependence and vascular inflammation through cotinine: A mediation analysis by Kumboyono Kumboyono, Indah N. Chomsy, Nadya N. Shalshabilla, Hidayat Sujuti, Arie Srihardyastutie, Cholid T. Tjahjono, Teuku Heriansyah, Titin A. Wihastuti

    Published 2024-01-01
    “…This study aimed to evaluate the relationship between NO levels and cotinine through the expression of nAChRs that mediate the nicotine dependence mechanism and Tie2 (Tyrosine Kinase 2) expression. Methods A cross-sectional study was conducted with 200 participants grouped into two groups based on their smoking status: 100 smokers and 100 non-smokers. …”
    Get full text
    Article
  7. 307
  8. 308

    Preserved Expression of Skin Neurotrophic Factors in Advanced Diabetic Neuropathy Does Not Lead to Neural Regeneration despite Pancreas and Kidney Transplantation by František Saudek, Monika Cahová, Terezie Havrdová, Klára Zacharovová, Helena Daňková, Luděk Voska, Věra Lánská, Nurcan Üçeyler, Claudia Sommer

    Published 2018-01-01
    “…Compared to DM and HC groups, we found a significantly higher (p < 0.05–0.001) expression of NGF (nerve growth factor), NGFR (NGF receptor), NTRK1 (neurotrophic receptor tyrosine kinase 1), GDNF (glial cell-derived neurotrophic factor), GFRA1 (GDNF family receptor alpha 1), and GFAP (glial fibrillary acidic protein) in both transplant groups (Tx1 and Tx2). …”
    Get full text
    Article
  9. 309

    De Novo Acute Myeloid Leukemia with Combined CBFB-MYH11 and BCR-ABL1 Gene Rearrangements: A Case Report and Review of Literature by Venkata Rakesh Sethapati, Ra’ed Jabr, Leyla Shune, Wissam El Atrouni, Patrick R. Gonzales, Wei Cui, Shivani Golem

    Published 2020-01-01
    “…The detection of t(9;22) led to the addition of daily doses of dasatinib (tyrosine kinase inhibitor) from day 7 onwards. The patient achieved complete remission on day 45. …”
    Get full text
    Article
  10. 310

    Conventional type 1 dendritic cells in the lymph nodes aggravate neuroinflammation after spinal cord injury by promoting CD8+ T cell expansion by Li-Qing Wang, Xiao-Yi Wang, Yue-Hui Ma, Heng-Jun Zhou

    Published 2025-02-01
    “…In vivo, the fms-like tyrosine kinase 3 (Flt3) inhibitor quizartinib was administered to deplete cDC1s, while intraperitoneal injection of recombinant Flt3L and immunosuppressive drug FTY-720 was used to expand cDC1s and prevent T cell egress from lymph nodes (LNs), respectively. …”
    Get full text
    Article
  11. 311

    Rescue of in vitro models of CSF1R-related adult-onset leukodystrophy by iluzanebart: mechanisms and therapeutic implications of TREM2 agonism by Kelley C. Larson, Frederick W. Gergits, Abigail J. Renoux, Elizabeth J. Weisman, Borislav Dejanovic, Liyue Huang, Bhaumik Pandya, Donald G. McLaren, Berkley A. Lynch, Richard Fisher, Evan Thackaberry, David Gray, Francois Gaudreault, Christian Mirescu

    Published 2025-01-01
    “…Similar functions have also been ascribed to triggering receptor expressed on myeloid cells 2 (TREM2), which shares an analogous microglia enrichment profile and converging intracellular signaling pathway mediated by spleen associated tyrosine kinase (SYK) and phosphoinositide-3-kinase (PI3K). …”
    Get full text
    Article
  12. 312

    Corticosterone-induced postpartum depression induces depression-like behavior and impairs hippocampal neurogenesis in adolescent offspring via HPA axis and BDNF-mTOR pathway by Hongxiao Xie, Yanning Jiang, Xiumeng Zhang, Xinran Min, Jiuseng Zeng, Li Chen, Nan Zeng, Rong Liu

    Published 2025-01-01
    “…We also found the offspring exhibited reduced expression of brain-derived neurotrophic factor (BDNF) and the phosphorylation tyrosine kinase receptor B (TrkB), protein kinase B (AKT), and mammalian target of rapamycin (mTOR) proteins in hippocampus. …”
    Get full text
    Article
  13. 313

    Functional Remediation Improves Serum BDNF and TrkB Levels in Euthymic Patients with Bipolar Disorder: A Randomized Trial Study by Li R, Li J, Ji SS, Li D, Chu L, Zhang J, Sun X, Luo X, Zhang Y

    Published 2025-01-01
    “…Ru Li,1,&ast; Jiaxin Li,1,&ast; Shiyi Suzy Ji,2 Dazhi Li,1 Lijun Chu,1 Jian Zhang,1 Xia Sun,1 Xingguang Luo,3 Yong Zhang1 1Unit of Bipolar Disorder, Tianjin Anding Hospital, Tianjin, People’s Republic of China; 2Department of Counseling and Clinical Psychology, Teachers College, Columbia University, NY, New York, USA; 3Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA&ast;These authors contributed equally to this workCorrespondence: Yong Zhang, Unit of Bipolar Disorder, Tianjin Anding Hospital, 13 Liulin Road, Hexi District, Tianjin, 300222, People’s Republic of China, Tel/Fax +86 22 8818 8258, Email zhangyong@tjmhc.comPurpose: We aimed to verify the impact of functional remediation (FR) on serum brain-derived neurotrophic factor (BDNF) and tyrosine kinase receptor B (TrkB) levels, to explore the biomechanism of FR intervention in patients with euthymic bipolar disorder (BD).Patients and Methods: This is a randomized controlled, 12-week intervention study with participants randomized into the FR group (n=39) and the treatment as usual group (TAU, n=42) at the 1∶1 ratio. 17-Hamilton Depression Rating Scale-17 (HDRS-17), Young Mania Rating Scale (YMRS), and Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) were used to assess affective symptoms and cognitive functioning both at baseline and week 12, respectively. …”
    Get full text
    Article
  14. 314

    Cross-Talk between NOK and EGFR: Juxtamembrane and Kinase domain interactions enhancing STAT3/5 signaling in breast cancer tumorigenesis by Yinyin Wang, Bingdong Zhang, Chunhua He, Bo Tian, Sihan Liu, Jianghua Li, Jiayu Wang, Shigao Yang, Bingtao Zhu, Xiaoguang Wang, Zhijie Chang, Chenxi Cao

    Published 2025-02-01
    “…Here we report that NOK (also known as STYK1), a novel tyrosine kinase cross-talks with EGFR to promote tumorigenesis and metastasis of breast cancer cells. …”
    Get full text
    Article
  15. 315

    ERK1/2 mitogen‐activated protein kinase dimerization is essential for the regulation of cell motility by Dalia de laFuente‐Vivas, Vincenzo Cappitelli, Rocío García‐Gómez, Sara Valero‐Díaz, Camilla Amato, Javier Rodriguéz, Santiago Duro‐Sánchez, Alexander vonKriegsheim, Michael Grusch, José Lozano, Joaquín Arribas, Berta Casar, Piero Crespo

    Published 2025-02-01
    “…Importantly, we unveil that the scaffold protein kinase suppressor of Ras 1 (KSR1) is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, to unleash cellular motion. …”
    Get full text
    Article
  16. 316

    Vision Improvement after Osimertinib Treatment in Paraneoplastic Optic Neuropathy Associated with Lung Adenocarcinoma by Masaomi Kubota, Nobumasa Tamura, Takaaki Hayashi, Euido Nishijima, Haruhiko Yanagisawa, Akira Kojima, Tadashi Nakano

    Published 2021-01-01
    “…Herein, we describe the clinical course of an older adult patient with PON whose loss of vision improved after switching between epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatments for cancer. …”
    Get full text
    Article
  17. 317

    Aberrant B cell receptor signaling responses in circulating double-negative 2 B cells from radiographic axial spondyloarthritis patients by Rick Wilbrink, Stefan F.H. Neys, Rudi W. Hendriks, Anneke Spoorenberg, Frans G.M. Kroese, Odilia B.J. Corneth, Gwenny M.P.J. Verstappen

    Published 2025-06-01
    “…Next, we explored B cell subset distribution and B-cell receptor (BCR) signaling responses in circulating B cells from 28 r-axSpA patients and 15 HCs, by measuring spleen tyrosine kinase, phosphoinositide 3-kinase and extracellular signal regulated kinase 1/2 phosphorylation upon α-Ig stimulation using phosphoflow cytometry. …”
    Get full text
    Article
  18. 318

    Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report by Meng LU, Ran ZHANG, Baiwei LI, Haidi XU, Yongkuan GUO, Jian YOU, Bingsheng SUN

    Published 2024-11-01
    “…For advanced NSCLC with METex14m, Savolitinib has a high sensitivity as a member of tyrosine kinase inhibitors (TKIs). METamp is a relatively rare genetic mutation type which can serve as a driver gene to mediate primary and later acquired drug resistance of epidermal growth factor receptor (EGFR)-TKIs. …”
    Get full text
    Article
  19. 319

    Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report by Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

    Published 2024-01-01
    “…New agents, including zongertinib, a HER2-selective tyrosine kinase inhibitor (TKI), are being investigated in clinical trials. …”
    Get full text
    Article
  20. 320

    Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages by Yuan Li, Yanping Chen, Yuan Meng, Meng Shen, Fan Yang, Xiubao Ren

    Published 2024-12-01
    “…Objective: The combination of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) leads to an increased incidence of severe immune-related adverse events (irAEs). …”
    Get full text
    Article